Therapeutic potential of a novel peripherally restricted CB1R inverse agonist on the progression of diabetic nephropathy
ObjectiveThis study assessed the efficacy of INV-202, a novel peripherally restricted cannabinoid type-1 receptor (CB1R) inverse agonist, in a streptozotocin-induced type-1 diabetes nephropathy mouse model.MethodsDiabetes was induced in 8-week-old C57BL6/J male mice via intraperitoneal injection of...
Main Authors: | Laetitia Jacquot, Océane Pointeau, Célia Roger-Villeboeuf, Patricia Passilly-Degrace, Rim Belkaid, Isaline Regazzoni, Julia Leemput, Chloé Buch, Laurent Demizieux, Bruno Vergès, Pascal Degrace, Glenn Crater, Tony Jourdan |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-03-01
|
Series: | Frontiers in Nephrology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fneph.2023.1138416/full |
Similar Items
-
Chemical Synthesis, Pharmacokinetic Properties and Biological Effects of JM-00266, a Putative Non-Brain Penetrant Cannabinoid Receptor 1 Inverse Agonist
by: Tania Muller, et al.
Published: (2022-03-01) -
Determination of the Cannabinoid CB1 Receptor’s Positive Allosteric Modulator Binding Site through Mutagenesis Studies
by: Hayley M. Green, et al.
Published: (2024-01-01) -
Neuroprotection and Beyond: The Central Role of CB1 and CB2 Receptors in Stroke Recovery
by: Bashir Bietar, et al.
Published: (2023-11-01) -
Editorial: Therapeutic potential of the cannabinoid CB2 receptor
by: Reem Smoum, et al.
Published: (2022-10-01) -
Involvement of CB1 and CB2 receptors in neuroprotective effects of cannabinoids in experimental TDP-43 related frontotemporal dementia using male mice
by: Claudia Gonzalo-Consuegra, et al.
Published: (2024-05-01)